Pieris Pharmaceuticals Inc. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
54.03 M |
Public Float |
53.88 M |
Pieris Pharmaceuticals Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$0.54 |
Market Cap |
$229.07 M |
Shares Outstanding |
49.26 M |
Public Float |
53.08 M |
Address |
255 State Street Boston Massachusetts 02109 United States |
Employees | - |
Website | http://www.pieris.com |
Updated | 07/08/2019 |
Pieris Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the discovery and development of Anticalin class of biotherapeutics. It offers technology to create differentiated drugs that can help patients suffering from cancer, severe asthma, anemia, and other medical conditions with an unmet medical need. The company was founded by Claus Schalper and Arne Skerra in 2001 and is headquartered in Boston, MA. |